Source:http://linkedlifedata.com/resource/pubmed/id/11830920
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2002-2-7
|
| pubmed:abstractText |
Between April 1994 and May 1997 103 breast cancer patients (pts), pT1c-3a, pN0-1, M0, were randomised after surgery to adjuvant tamoxifen (20 mg per day) or to tamoxifen plus CMF (C 500 mg/m2, M 40 mg/m2 and F 600 mg/m2 on days 1st and 8th q 28 day) in 6 cycles. The median age (49-72 years, median 58), tumour size, number of involved lymphnodes (0-3), estrogens receptor status, grade (I-III) and type of operation were well balanced among the 50 pts on tamoxifen and the 53 pts on tamoxifen plus CMF pts, preferably postmenopausal. RESULTS: Grade of toxicity according to WHO criteria was not higher then two in both arms. Toxicity both haematological and non-haematological was higher in the group treated with chemotherapy (0 vs 32 resp. 20%) except weight gain (52% in both group). After median follow-up of 42 mos five recurrences in tamoxifen and seven in tamoxifen plus CMF pts were observed (p = NS). The projected 3-y DFS is 92% for tamoxifen and 88% for tamoxifen plus CMF (p = NS). The 3-y OS is 88% for tamoxifen and 80% for tamoxifen plus CMF pts (p = NS). CONCLUSIONS: Both regimens are equally effective with higher toxicity in the group with combined chemo- and hormonal therapy.
|
| pubmed:language |
cze
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0036-5327
|
| pubmed:author |
pubmed-author:BauerJJ,
pubmed-author:BustováII,
pubmed-author:DorazilováVV,
pubmed-author:FischerJJ,
pubmed-author:HacklováMM,
pubmed-author:HonováHH,
pubmed-author:K?taMM,
pubmed-author:KohoutekMM,
pubmed-author:KyseláTT,
pubmed-author:MachácekJJ,
pubmed-author:MillerVV,
pubmed-author:PetruzelkaLL,
pubmed-author:PribylovàHH,
pubmed-author:SiffnerováHH,
pubmed-author:SurSS,
pubmed-author:TajblováJJ,
pubmed-author:VedralováJJ,
pubmed-author:VodvárkaPP
|
| pubmed:issnType |
Print
|
| pubmed:volume |
102
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
65-76
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading |
pubmed-meshheading:11830920-Aged,
pubmed-meshheading:11830920-Antineoplastic Agents, Hormonal,
pubmed-meshheading:11830920-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11830920-Breast Neoplasms,
pubmed-meshheading:11830920-Chemotherapy, Adjuvant,
pubmed-meshheading:11830920-Female,
pubmed-meshheading:11830920-Humans,
pubmed-meshheading:11830920-Middle Aged,
pubmed-meshheading:11830920-Survival Rate,
pubmed-meshheading:11830920-Tamoxifen
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
[Tamoxifen or tamoxifen in combination with chemotherapy in adjuvant therapy of breast carcinoma. Results of a multicenter randomized study].
|
| pubmed:affiliation |
Onkologická klinika 1: lékarské fakulty Univerzity Karlovy, U nemocnice 2, 128 08 Praha 2, Czech Republic. onkol@lf1.cuni.cz
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|